Arachidonate 5-Lipoxygenase (ALOX5) gene polymorphism is associated with Alzheimer's disease and body mass index
Authors | |
---|---|
Year of publication | 2016 |
Type | Article in Periodical |
Magazine / Source | Journal of the neurological sciences |
MU Faculty or unit | |
Citation | |
Doi | http://dx.doi.org/10.1016/j.jns.2016.01.022 |
Field | Neurology, neurosurgery, neurosciences |
Keywords | Alzheimer's disease; Arachidonic acid; Association; Caffeic acid; Curcumin; FLAP; Genetics; Inflammation; Leukotrienes; Polymorphism |
Description | Dementias of old age, in particular Alzheimer's disease (AD), pose a growing threat to the longevity and quality of life of individuals as well as whole societies world-wide. The risk factors are both genetic and environmental (life-style) and there is an overlap with similar factors predisposing to cardiovascular diseases (CVD). Using a case-control genetic approach, we have identified a SNP (rs10507391) in ALOX5 gene, previously associated with an increased risk of stroke, as a novel genetic risk factor for AD. ALOX5 gene encodes a 5-lipoxygenase (5-LO) activating protein (FLAP), a crucial component of the arachidonic acid/leukotriene inflammatory cascade. A-allele of rs4769874 polymorphism increases the risk of AD 1.41-fold (p = 0.0001), while AA genotype does so 1.79-fold (p = 0.0001). In addition, GG genotype of rs4769874 polymorphism is associated with a modest increase in body mass index (BMI). We discuss potential biochemical mechanisms linking the SNP to AD and suggest possible preventive pharmacotherapies some of which are based on commonly available natural products. Finally, we set the newly identified AD risk factors into a broader context of similar CVD risk factors to generate a more comprehensive picture of interacting genetics and life-style habits potentially leading to the deteriorating mental health in the old age. |
Related projects: |